Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Nicholas C, Kingston, Belinda, Kilburn, Lucy S, Kernaghan, Sarah, Wardley, Andrew M, Macpherson, Iain R, Baird, Richard D, Roylance, Rebecca, Stephens, Peter, Oikonomidou, Olga, Braybrooke, Jeremy P, Tuthill, Mark, Abraham, Jacinta, Winter, Matthew C, Bye, Hannah, Hubank, Michael, Gevensleben, Heidrun, Cutts, Ros, Snowdon, Claire, Rea, Daniel, Cameron, David, Shaaban, Abeer, Randle, Katrina, Martin, Sue, Wilkinson, Katie, Moretti, Laura, Bliss, Judith M, Ring, Alistair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599319/
https://www.ncbi.nlm.nih.gov/pubmed/32919527
http://dx.doi.org/10.1016/S1470-2045(20)30444-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599319/
https://www.ncbi.nlm.nih.gov/pubmed/32919527
http://dx.doi.org/10.1016/S1470-2045(20)30444-7

Ejemplares similares